Registry-listed formulations

Betamethasone Valerate · chembl:CHEMBL1497

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

21 source entries across 19 studies. This list may not include all unresolved or historical entries.

  • Betamethasone valerateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • betamethasone valerateRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • betamethasone valerateRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • betamethasone valerateRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • betamethasone valerateRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • betamethasone valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.1% betamethasone valerate creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone ValerateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone 17-valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone valerate 0.1%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • betamethasone valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone Valerate CreamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone ValerateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Topical betamethasone valerate 0.1%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • BETAMETHASONE VALERATERegistry product

    Molecular identity unconfirmed

    Formulation reported by source: OINTMENT

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source
  • Betamethasone ValerateRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone Valerate 0.1% CreamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Betamethasone valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • betamethasone valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • betamethasone valerate 0.1% creamRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
3(15%)
Results Posted
10%(1 trials)

Phase Distribution

Phase 2/3
1
5%
Phase 3
5
25%
Phase 4
5
25%
Phase 2
1
5%
Phase 1
3
15%
Not Applicable
4
20%

Phase Distribution

3

Early Stage

2

Mid Stage

10

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
3(15.8%)
Phase 2Efficacy & side effects
1(5.3%)
Phase 2/3Combined phases
1(5.3%)
Phase 3Large-scale testing
5(26.3%)
Phase 4Post-market surveillance
5(26.3%)
N/ANon-phased studies
4(21.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

20

all time

Status Distribution
Active(5)
Completed(10)
Other(5)

Detailed Status

Completed10
unknown5
Recruiting2
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.8%)
Phase 21 (5.3%)
Phase 2/31 (5.3%)
Phase 35 (26.3%)
Phase 45 (26.3%)
N/A4 (21.1%)

Trials by Status

unknown525%
recruiting210%
active_not_recruiting15%
completed1050%
not_yet_recruiting210%

Recent Activity

3 active trials
Showing 5 of 20
recruitingphase_4

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

NCT07508124
not_yet_recruitingnot_applicable

New Topical Treatment in Patchy Alopecia Areata

NCT07696585
active_not_recruitingphase_2_3

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
not_yet_recruitingnot_applicable

Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis

NCT07366268
completedphase_2

Skin bioMARkers for Atopic Eczema Therapy Evaluation

NCT04194814
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07508124Phase 4

Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study

Recruiting
NCT07696585Not Applicable

New Topical Treatment in Patchy Alopecia Areata

Not Yet Recruiting
NCT05535738Phase 2/3

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Active Not Recruiting
NCT07366268Not Applicable

Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis

Not Yet Recruiting
NCT04194814Phase 2

Skin bioMARkers for Atopic Eczema Therapy Evaluation

Completed
NCT05285943Phase 4

Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients

Completed
NCT06643416Phase 3

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Recruiting
NCT06267066Not Applicable

Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus

Unknown
NCT06140186Phase 3

Efficacy and Safety of Timolol for TKI Induced Paronychia

Unknown
NCT05803070

Topical Cetirizine in Treatment of Localized Alopecia Areata

Unknown
NCT05555797Phase 4

Excimer Laser With Topical Agents in Psoriasis Vulgaris

Unknown
NCT04476420Phase 3

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Completed
NCT00358384Phase 1

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

Completed
NCT02548052Phase 1

Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis

Completed
NCT02443311Phase 4

Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus

Completed
NCT01646567Phase 1

SHP-141C in Plaque Type Psoriasis

Completed
NCT01011621Phase 3

Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis

Unknown
NCT00576238Phase 3

Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser

Completed
NCT00576550Phase 4

A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema

Completed
NCT00608673Not Applicable

Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

Completed

All 20 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
20

External References

ChEMBL
CHEMBL1497

Names & Codes

Research Codes

NSC-755912